Antipsychotic medication list

An antipsychotic medication list is a structured reference that organizes psychiatric drugs by generation, mechanism, FDA-approved indication, and monitoring requirement. Antipsychotics work by modulating dopamine and serotonin pathways in the brain, which reduces hallucinations, delusions, and disorganized thinking. The list below covers both generations, their usual daily doses, and the checks each one needs.

The split between first-generation (typical) and second-generation (atypical) agents drives most prescribing decisions. First-generation drugs carry a higher risk of extrapyramidal side effects, such as tardive dyskinesia and akathisia. Second-generation drugs carry more metabolic risk, including weight gain, dyslipidemia, and hyperglycemia.

This template gives psychiatrists, primary care physicians, and nursing staff one standard place to document and review antipsychotic prescriptions. Psychiatry practice software keeps those records inside the patient chart, and a printed reference keeps the team aligned on dosing, monitoring intervals, and contraindications.

Key takeaways

Antipsychotics are dopamine antagonists used to treat schizophrenia, bipolar disorder, and schizoaffective disorder.

First-generation agents cause more extrapyramidal side effects, while second-generation agents carry more metabolic risk, so each needs its own monitoring priorities.

Clozapine carries a boxed warning for severe neutropenia and needs absolute neutrophil count monitoring on a fixed schedule.

Every antipsychotic needs baseline metabolic screening, a repeat check at 12 weeks, and an EPS assessment at review.

The downloadable template standardizes medication documentation, side-effect tracking, and review schedules across your practice team.

What are antipsychotic medications?

Antipsychotics are a class of psychiatric medications that block dopamine receptors in the brain, and second-generation agents block serotonin receptors as well. They manage psychotic symptoms such as hallucinations, delusions, and disorganized thought and speech. They also stabilize mood in bipolar disorder.

Three major clinical indications guide prescribing:

• Schizophrenia: First-line treatment for acute psychosis, and maintenance therapy to prevent relapse.
• Bipolar disorder: FDA-approved agents manage acute manic episodes and maintain mood stability, and some also treat bipolar depression.
• Schizoaffective disorder: Psychotic and mood symptoms occur together, and antipsychotics address the psychotic component.

The National Institute of Mental Health describes antipsychotics as the cornerstone of pharmacotherapy for schizophrenia and acute psychotic episodes. Bipolar regimens often pair one with lithium or another agent, so keep a mood stabilizer medication list next to this one.

Off-label use extends to treatment-resistant depression as an adjunct, severe anxiety disorders, and dementia-related agitation, though the evidence varies. Any off-label prescription needs a documented clinical rationale and patient consent.

Typical vs atypical antipsychotics: Key differences

The two generations differ in their side-effect profiles and in how they are used:

Second-generation agents are now first-line for most newly diagnosed patients, mainly because they are better tolerated. First-generation drugs remain in use for cost, availability, and specific patient populations. Clozapine, the standard for treatment-resistant schizophrenia, sits apart due to its agranulocytosis and severe neutropenia risk and mandatory absolute neutrophil count (ANC) monitoring.

First-generation antipsychotics list

First-generation antipsychotics remain clinically important despite the higher EPS burden. The table below summarizes the agents prescribed most often.

Second-generation antipsychotics list

Second-generation antipsychotics dominate modern psychiatric practice. Each agent has its own FDA-approved indications and metabolic risk profile.

Clozapine carries a boxed warning for severe neutropenia. ANC monitoring is required under the prescribing information, and the result belongs in the patient record at every check.

Long-acting injectable antipsychotics

Injectable formulations release medication over weeks or months, which improves adherence during maintenance therapy. Long-acting injectables are offered for haloperidol and fluphenazine (decanoate), risperidone, paliperidone, aripiprazole, and olanzapine. Dosing intervals run from 2 weeks to every 3 months, and paliperidone extends to every 6 months.

Clinicians reach for these formulations when a patient has relapsed after stopping oral treatment.

Side effects of antipsychotic medications

All antipsychotics carry risks, and knowing them guides both prescribing and patient counseling:

• Extrapyramidal side effects (EPS): Tremor, muscle stiffness, restlessness (akathisia), and dystonia, all more common with first-generation agents. Tardive dyskinesia emerges with long-term use and may be irreversible.
• Metabolic effects: Weight gain, hyperglycemia, and dyslipidemia, with olanzapine and clozapine carrying the highest risk. Baseline screening and a 12-week recheck of glucose and lipids are recommended.
• Prolactin elevation: Galactorrhea, sexual dysfunction, and amenorrhea. Risperidone carries the highest risk among second-generation drugs.
• Cardiac effects: QT interval prolongation, rare but serious with ziprasidone and clozapine. A baseline ECG is recommended where QT risk exists.

Monitoring requirements for antipsychotic therapy

Monitoring follows the ADA/APA consensus on metabolic risk in patients taking antipsychotics. Track the following at baseline and at the intervals below.

• Baseline: Weight and BMI, blood pressure, fasting glucose, lipid panel, prolactin, an EPS rating scale (AIMS or Simpson-Angus), and an ECG where QT risk exists.
• Weeks 4, 8, and 12: Weight and BMI at every visit.
• Week 12: Repeat the blood pressure, fasting glucose, and lipid panel.
• Every 3 months after week 12: Weight and BMI.
• Annually: Blood pressure, fasting glucose, and an EPS assessment. Check prolactin where symptoms appear.
• Every 5 years: Lipid panel, if the baseline and week 12 results were normal.
• Clozapine: Baseline ANC, then weekly for the first 6 months, every 2 weeks for months 6 to 12, then monthly.

Read down that schedule and one pattern stands out. Weight is checked four times before any laboratory test repeats, because it moves first.

Digital intake forms turn that schedule into fields staff actually complete. In Pabau, the practice management platform we build, each result is dated and attached to the patient record.

Dated, auditable monitoring records protect the patient and the prescriber. A missed interval is easier to catch when the last result is visible on the chart.

How to use the template

The template is structured around five practical steps:

1. Review approved indications: Cross-check each patient’s diagnosis against the agent’s FDA-approved indication. Document any off-label use with its clinical justification.
2. Document baseline monitoring: Record weight, blood pressure, the metabolic panel, prolactin, and the baseline EPS score. These become the reference for every follow-up visit.
3. Track dosage and formulation: Note the generic name, brand name, route (oral or long-acting injectable), strength, and daily dose. Flag each dose change with its date and reason.
4. Schedule monitoring intervals: Set reminders for the 12-week recheck and the quarterly weight review. The template’s review-date field keeps the team on schedule.
5. Flag high-risk medications: Where clozapine is prescribed, record the ANC monitoring schedule and the date of the last result.

An AI medical scribe can capture medication review findings during the visit. The note is written as the conversation happens, so the prescriber is not typing it up afterward.

Who should use it

The template serves several roles in a practice. Psychiatrists use it for schizophrenia and bipolar mania management. Primary care physicians reference it when they co-manage a psychotic or mood disorder with a specialist.

Nursing staff, physician assistants, and nurse practitioners use it during intake and at follow-up medication review. Ward teams often pair it with a schizophrenia nursing care plan. A mental health EMR holds the same fields in the chart, so the printed copy and the record agree.

Practice administrators use it to audit medication management and confirm that high-risk monitoring was completed on time.

Benefits of standardized medication documentation

Standardized documentation: A uniform structure means no medication or monitoring requirement is overlooked. Consistency across prescribers reduces errors and supports safe transitions of care.

Regulatory compliance: The monitoring intervals follow the American Psychiatric Association and ADA consensus on metabolic monitoring in patients taking antipsychotics. Dated records demonstrate due diligence during an audit or a malpractice review.

Patient safety: Early detection of metabolic change, emerging EPS, or QT prolongation prevents serious adverse events. An organized schedule reduces missed assessments.

Workflow efficiency: Pre-built fields speed up charting, and connected practice management keeps the same data in the appointment, the prescription, and the recall.

How Pabau keeps antipsychotic monitoring on schedule

Antipsychotic monitoring is usually tracked in two places at once. The prescription sits in the chart, and the recall for the 12-week bloods sits in a diary or a spreadsheet. When the patient reschedules, the recall rarely moves with them.

In Pabau, the medication record and the recall are the same object. A custom form holds the drug, the dose, and each monitoring result. The review date drives an automated reminder to the patient and a task for the prescriber.

Each result is timestamped as it is entered, so the next due date updates without anyone maintaining a separate tracker. Pabau Scribe writes the medication review straight into the note, and reporting lists every patient whose 12-week bloods are overdue.

The result is one record per patient holding the prescription, the monitoring history, and the next due date. Staff no longer reconcile a chart against a spreadsheet at the end of the month.

Keep antipsychotic monitoring on schedule

Pabau stores the prescription, the monitoring results, and the review date in one patient record. Automated recalls bring patients back for the checks their medication needs.

Book a demo

Conclusion

Choosing an antipsychotic is the shorter half of the job. The longer half is proving, months later, that the weight checks and the bloods happened on time.

Download the template and keep it where prescriptions are written, rather than in a shared drive. A reference that sits beside the chart gets filled in. The trade-off worth remembering is that paper records a decision but will not chase it, so the review date still needs an owner.

Book a demo to see how Pabau turns that review date into a recall your team does not have to remember.

Continue your research

Need the full first-visit assessment? Psychiatric evaluation template covers the mental status examination and treatment planning in one document.

Prescribing for bipolar disorder too? Manic depression medication list sets out the agents used across manic and depressive phases.

Managing a schizophrenia admission? Schizophrenia system disorder template structures the nursing assessment and the care priorities.

Tracking stimulant side effects as well? ADHD medication side effects monitoring sheet records appetite, sleep, and growth at each review.

Need a structured first appointment? Psychiatry intake form gathers history, risk, and current medication before the consultation.

Frequently asked questions